Aster Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.48M Buy
2,374
+2,366
+29,575% +$1.61M 0.31% 93
2026
Q1
$5.07K Sell
8
-264
-97% -$202K ﹤0.01% 683
2025
Q4
$210K Buy
272
+157
+137% +$107K 0.09% 213
2025
Q3
$64.7K Buy
+115
New +$65K 0.03% 458
2025
Q2
Sell
-2,653
Closed -$1.85M 1484
2025
Q1
$1.85M Buy
+2,653
New +$1.82M 0.34% 60
2024
Q4
Sell
-1,084
Closed -$1.14M 1448
2024
Q3
$1.14M Buy
+1,084
New +$1.21M 0.25% 101

Other funds holding REGN

Aster Capital Management's REGN Position: Q2 2026 in Review

Aster Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 29,575% in Q2 2026, buying an estimated $1.61M and bringing the position to 2,374 shares worth $1.48M. The position accounts for 0.31% of the portfolio, ranked #93.

Aster Capital Management first reported a position in REGN in Q3 2024 and has held it in 6 quarters since. The position peaked at $1.85M in Q1 2025. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Aster Capital Management held 2,374 shares of Regeneron Pharmaceuticals worth $1.48M as of Q2 2026.
  • Aster Capital Management bought 2,366 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.61M.
  • Regeneron Pharmaceuticals made up 0.31% of Aster Capital Management's portfolio in Q2 2026, its #93 holding.
  • Aster Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • Aster Capital Management's Regeneron Pharmaceuticals position peaked at $1.85M in Q1 2025.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.